TY  - JOUR
AU  - Paz-Ares, Luis
AU  - Forster, Martin
AU  - Boni, Valentina
AU  - Szyldergemajn, Sergio
AU  - Corral, Jesús
AU  - Turnbull, Samantha
AU  - Cubillo, Antonio
AU  - Teruel, Carlos Fernandez
AU  - Calderero, Iker López
AU  - Siguero, Mariano
AU  - Bohan, Patrick
AU  - Calvo, Emiliano
PY  - 2016
DO  - 10.1007/s10637-016-0410-3
UR  - http://hdl.handle.net/10668/10626
T2  - Investigational new drugs
AB  - Background To determine the recommended dose (RD) of a combination of PM01183 and gemcitabine in patients with advanced solid tumors. Methods Forty-five patients received escalating doses of PM01183/gemcitabine on Days 1 and 8 every 3 weeks (d1,8...
LA  - en
KW  - Combination
KW  - Gemcitabine
KW  - Lurbinectedin
KW  - PM01183
KW  - Solid tumor
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carbolines
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Female
KW  - Heterocyclic Compounds, 4 or More Rings
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - Treatment Outcome
KW  - Gemcitabine
TI  - Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
TY  - research article
VL  - 35
ER  -